애로우헤드 파마슈티컬스, Inc.
US ˙ NasdaqGS ˙ US04280A1007

SecurityARWR / Arrowhead Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership209,014 shares
Latest Disclosed Value $ 3,302,421
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 2.73% increase in ownership of ARWR / Arrowhead Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 209,014 shares of Arrowhead Pharmaceuticals, Inc. (US:ARWR) valued at $3,302,421 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 203,454 shares of Arrowhead Pharmaceuticals, Inc.. This represents a change in shares of 2.73% during the quarter. The current value of the position is $15,276,833 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 209,014 5,560 2.73 3,302 27.39 0.0742
2025-05-28 2025-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 203,454 2,160 1.07 2,592 -31.50 0.0622
2025-02-25 2024-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 201,294 -32,567 -13.93 3,784 -16.45 0.0826
2024-11-26 2024-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 233,861 13,160 5.96 4,530 -21.04 0.0857
2024-08-26 2024-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 220,701 15,673 7.64 5,736 -2.17 0.1168
2024-05-28 2024-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 205,028 20,785 11.28 5,864 4.01 0.1224
2024-02-26 2023-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 184,243 12,659 7.38 5,638 22.28 0.1203
2023-11-28 2023-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 171,584 -5,595 -3.16 4,610 -27.03 0.1203
2023-08-25 2023-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 177,179 12,247 7.43 6,318 50.82 0.1498
2023-05-26 2023-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 164,932 2,532 1.56 4,189 -36.40 0.1116
2023-02-24 2022-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 162,400 -855 -0.52 6,587 22.08 0.1812
2022-11-25 2022-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 163,255 4,236 2.66 5,396 -3.64 0.1546
2022-08-25 2022-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 159,019 1,409 0.89 5,599 -22.75 0.1546
2022-05-26 2022-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 157,610 2,362 1.52 7,248 -29.58 0.1689
2022-02-25 2021-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 155,248 1,076 0.70 10,293 6.94 0.2232
2021-11-24 2021-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 154,172 779 0.51 9,625 -24.24 0.2120
2021-08-26 2021-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 153,393 -1,911 -1.23 12,704 23.36 0.2725
2021-05-27 2021-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 155,304 -1,612 -1.03 10,298 -14.47 0.2335
2021-02-25 2020-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 156,916 -7,135 -4.35 12,040 70.44 0.3085
2020-11-25 2020-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 164,051 -5,438 -3.21 7,064 -3.50 0.2267
2020-08-27 2020-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 169,489 6,664 4.09 7,320 56.28 0.2393
2020-06-01 2020-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 162,825 17,167 11.79 4,684 -49.30 0.1915
2020-02-27 2019-12-31 NP Arrowhead Pharmaceuticals EC 04280A100 145,658 2,709 1.90 9,239 129.37 0.2778
2019-11-27 2019-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 142,949 142,949 4,028 0.1332
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.